Sulfonylurea Equivalence and Efficacy

Medication Comparison

• Glimepiride and gliclazide are both second-generation sulfonylureas that stimulate insulin secretion from pancreatic β-cells and have high glucose-lowering efficacy, as recommended by the American Diabetes Association 1, 2
• Both medications are considered newer-generation sulfonylureas that confer a lower risk of hypoglycemia compared to older agents like glibenclamide, according to the American College of Clinical Endocrinologists 1, 3

Safety Profile

• For patients with renal impairment, dosing adjustments may be needed for both medications, but gliclazide may be preferred in patients with GFR <30 ml/min/1.73 m², as suggested by the National Kidney Foundation 4

Clinical Considerations

• The choice between glimepiride and gliclazide should consider individual patient factors including hypoglycemia risk, renal function, and cost, as recommended by the American Association of Clinical Endocrinologists 1, 3

Cost Considerations

• Both medications are available as generics and are relatively inexpensive compared to newer classes of antidiabetic medications, according to the American Diabetes Association 5
• Glimepiride 4 mg has a median AWP of $73 and NADAC of $3 for a 30-day supply, as reported by the Centers for Medicare and Medicaid Services 6